Get the Stockscreener App
35.80
2.76%
0.96
After Hours:
35.80
Zenas Biopharma Inc stock is traded at $35.80, with a volume of 240.15K.
It is up +2.76% in the last 24 hours and up +37.53% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$34.84
Open:
$34.84
24h Volume:
240.15K
Relative Volume:
0.61
Market Cap:
$1.92B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.29%
1M Performance:
+37.53%
6M Performance:
+227.24%
1Y Performance:
+242.91%
1-Day Range:
$33.89
$36.50
1-Week Range:
$33.80
$38.50
52-Week Range:
$5.83
$38.50
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
35.80 | 1.87B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Zenas BioPharma : Corporate Presentation - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Will Zenas BioPharma Inc. benefit from macro trendsEarnings Beat & Verified High Yield Trade Plans - newser.com
Is Zenas BioPharma Inc. stock a dividend growth opportunityDollar Strength & High Conviction Investment Ideas - newser.com
Will Zenas BioPharma Inc. stock keep outperforming rivalsMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Will Zenas BioPharma Inc. stock remain a Wall Street favoriteEarnings Performance Report & Risk Controlled Swing Alerts - newser.com
What analysts say about Zenas BioPharma Inc stockMomentum Trading Signals & Low Cost Market Strategies - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
What dividend safety score for Zenas BioPharma Inc. stockTrade Exit Summary & Long Hold Capital Preservation Tips - newser.com
Price momentum metrics for Zenas BioPharma Inc. explainedBuy Signal & Fast Moving Stock Watchlists - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Strategies to average down on Zenas BioPharma Inc.2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
2025-11-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect | NDAQ:ZBIO | Press Release - Stockhouse
Zenas Biopharma stock hits all-time high at 36.7 USD By Investing.com - Investing.com Nigeria
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - Nasdaq
Will Zenas BioPharma Inc. stock sustain high P E ratiosMarket Sentiment Report & Daily Stock Trend Reports - newser.com
2025-11-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out | NDAQ:ZBIO | Press Release - Stockhouse
How risky is Zenas BioPharma Inc. stock nowBull Run & Real-Time Chart Breakout Alerts - newser.com
Is Zenas BioPharma Inc. stock ready for breakoutEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Published on: 2025-11-15 02:01:43 - newser.com
Zenas BioPharma Reports Q3 2025 Financial Results - TipRanks
How to track smart money flows in Zenas BioPharma Inc.Trade Risk Report & Safe Entry Trade Signal Reports - newser.com
How Zenas BioPharma Inc. stock reacts to inflationary pressuresGap Down & Free Long-Term Investment Growth Plans - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma price target raised to $37 from $34 at Morgan Stanley - TipRanks
Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating - TipRanks
Decoding Zenas BioPharma Inc (ZBIO): A Strategic SWOT Insight - GuruFocus
Zenas BioPharma, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2025 - MarketScreener
Zenas BioPharma Q3 Net Loss Narrows - MarketScreener
Earnings Flash (ZBIO) Zenas BioPharma Posts Q3 Net Loss $1.22 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener
Zenas BioPharma, Inc. SEC 10-Q Report - TradingView
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):